Xencor | XNCR - Assets


Xencor reported $868.81M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Amgen USD 90.59B 445M Dec/2025
Arrowhead Research USD 1.6B 218.89M Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
Biogen USD 29.44B 232M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Cytokinetics USD 1.42B 12.02M Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
J&J USD 199.21B 6.39B Dec/2025
Karyopharm Therapeutics USD 96.23M 8.65M Sep/2025
MacroGenics USD 270.76M 25.34M Sep/2025
Merck USD 129.55B 12.02B Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Xencor USD 868.81M 10.61M Sep/2025